Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Abatacept/cyclophosphamide

Lack of efficacy and off-label use in unapproved indication

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kaur S, et al. Graft-Versus-Host Disease (GvHD) Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation (haplo-PBSCT) Using Abatacept in Combination with Post-Transplant Cyclophosphamide (PTCy). Blood 142 (Suppl.): 6996-6997, Nov 2023. Available from: URL: https://dx.doi.org/10.1182/blood-2023-184901 [abstract] Kaur S, et al. Graft-Versus-Host Disease (GvHD) Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation (haplo-PBSCT) Using Abatacept in Combination with Post-Transplant Cyclophosphamide (PTCy). Blood 142 (Suppl.): 6996-6997, Nov 2023. Available from: URL: https://​dx.​doi.​org/​10.​1182/​blood-2023-184901 [abstract]
Metadaten
Titel
Abatacept/cyclophosphamide
Lack of efficacy and off-label use in unapproved indication
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57908-0

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Tozinameran

Case report

Multiple drugs

Case report

Misoprostol

Case report

Isoniazid